期刊文献+

芳香化酶抑制剂致乳腺癌患者关节痛的病因及防治 被引量:4

Aromatase inhibitor-associated arthralgia's etiology and treatment in patients with breast cancer
在线阅读 下载PDF
导出
摘要 芳香化酶抑制剂(AIs)已经广泛用于绝经后雌激素受体阳性的乳腺癌患者的术后辅助治疗。与单独应用他莫昔芬相比,AIs能显著地提高治疗效果,但同时也会带来骨肌系统的副作用,主要包括骨丢失和关节痛,而这已成为导致治疗中断的主要因素。本文对芳香化酶抑制剂导致关节痛的可能病因及治疗进展进行综述。 Aromatase inhibitors are widely used as adjuvant therapy in postmenopausal women with hormone receptor -positive breast cancer.While the agents are associated with slightly improved survival outcomes when compared to tamoxifen alone,bone and musculoskeletal side effects are substantial,including bone loss and arthralgias,which have been the main causes of discontinuation of therapy.This review will focus on possible causes and treatment progress of aromatase inhibitors-associated arthralgias.
出处 《现代肿瘤医学》 CAS 2013年第11期2631-2635,共5页 Journal of Modern Oncology
关键词 乳腺癌 关节痛 芳香化酶抑制剂 breast cancer arthralgia aromatase inhibitor
作者简介 作者简介:牛雪姣(1987-),女,天津人,在读硕士,主要从事肿瘤的中西医结合基础及实验研究.E-mail:nxjnxj87@sina.com 姚嫱(1964-),女,天津人,主任医师,硕士生导师,主要从事恶性肿瘤综合治疗.E-mail:tjyaoqiang126@126.com
  • 相关文献

参考文献44

  • 1Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline:update on adjuvant endocrine therapy for women with hormone receptor - positive breast cancer[ J ]. J Clin Onco1,2010,28 (23) :3784 - 3796.
  • 2Dixon JM, Renshaw L, Young O, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopansal women with breast cancer[ J]. J Clin Onco1,2008, 26(10) :1671 - 1676.
  • 3Bago - Horvath Z, Rudas M, Dubsky P, et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant sequencing of tamoxifen and anastrezole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer[ J ]. Clin Cancer Res, 2011,17 (24) :7828 - 7834.
  • 4Fonseca M, Araajo GT, Saad ED. Cost -effectiveness of anastre- zole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil [ J ]. Rev Assoc Med Bras, 2009,55 (4) :410 -415.
  • 5Henry NL, Giles Jr, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors [J]. Breast Cancer Res Treat, 2008,111 (2) :365 - 372.
  • 6Moxley G. Rheumatic disorders and functional disability with are- matase inhibitor therapy [ J ]. Clin Breast Cancer,2010,10 (2) : 144 - 147.
  • 7Khan QJ, ODea AP, Sharma P. Musculoskeletal adverse events as- sociated with adjuvant arematase inhibitors [ J ]. J Oncol, 2010,2 : 554348.
  • 8Nabholtz JM. Long - term safety of aromatase inhibitors in the treat- ment of breast cancer[ J]. Ther Clin Risk Manag,2008,4 ( 1 ) :189 - 204.
  • 9Nagyk61nai T, Landherr L, M6sz6res E. Aromatase inhibitors and arthralgia[ J]. Magy Onkol,2011,55( 1 ) :32 -39.
  • 10Mao J J, Stricker C, Bruner D, et al. Patterns and risk factors asso- ciated with aromatase inhibitor - related arthralgia among breast cancer survivors[ J]. Cancer,2009,115 ( 16 ) :3631 - 3639.

同被引文献58

  • 1沈镇宙,宋三泰,张斌,邵志敏,陆劲松.中国绝经前女性乳腺癌患者辅助治疗后绝经判断标准及芳香化酶临床应用共识(草案修正案)[J].中国癌症杂志,2011,21(5):418-420. 被引量:19
  • 2吴世凯,宋三泰.第三代芳香化酶抑制剂临床应用的常见不良反应[J].中国药物警戒,2006,3(2):68-71. 被引量:15
  • 3闫振北,韩明强.雌激素水平影响他莫昔芬抑制乳腺癌细胞生长的机制探讨[J].中国医刊,2008,43(1):57-58. 被引量:4
  • 4DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013[J]. CA Cancer J C1in,2014,64( 1 ) :52 -62.
  • 5Malvezzi M, Bertuccio P, Rosso T, et al. European cancer mor- tality predictions for the year 2015 : does lung cancer have the highest death rate in EU women [ J]. Ann Oncol, 2015,26 (4) :779 -786.
  • 6Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer in- cidence and mortality patterns in Europe : estimates for 40 countries in 2012[ J]. Eur J Cancer.2013.49(6) :1374 - 1403.
  • 7Jemal A, Siegel R, Xu J, et al. Cancer Statistics [ J ]. CA Cancer J Clin ,2010,60 ( 5 ) :277 - 300.
  • 8Burstein H J, Prestrud AA, Seidenfeld J, et al. American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer[ J]. J ClinOncol,2010,28(23) :3784-3796.
  • 9Dowsett M, Forbes JF, Bradle R, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials [J]. Lancet,2015,386( 10001 ) ;1341 - 1352.
  • 10Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by No|vadex Adjuvant Trial Organisation [ J ]. Lancet, 2015,386 ( 10001 ) : 1341 - 1352.

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部